ReviewPharmacoEconomics - open2018
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.
Review in PharmacoEconomics - open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.PharmacoEconomics · 2019Pooled it
- Alternative Payment Models for Innovative Medicines: A Framework for Effective Implementation.Applied health economics and health policy · 2025Article
- Risk-sharing agreements for medical devices: a stakeholder-based qualitative study in Czechia.Frontiers in public health · 2025Article
- Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.PharmacoEconomics · 2025Article
- Value-based payment for high-cost treatments in Singapore: a qualitative study of stakeholders' perspectives.International journal of technology assessment in health care · 2024Article
- Reporting reimbursement price decisions for onco-hematology drugs in Spain.Frontiers in public health · 2023Article
- Country versus pharmaceutical company interests for hepatitis C treatment.Health care management science · 2022Article
- How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?Iranian journal of pharmaceutical research : IJPR · 2022Article
- Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.International journal of environmental research and public health · 2022Article
- The value of anticancer drugs - a regulatory view.Nature reviews. Clinical oncology · 2022Review
- The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada.Healthcare policy = Politiques de sante · 2022Article
- Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies.BMC health services research · 2021Article
- Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.Healthcare (Basel, Switzerland) · 2021Article
- Integrative Review of Managed Entry Agreements: Chances and Limitations.PharmacoEconomics · 2020Review
- Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Development and Use of Gene Therapy Orphan Drugs-Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society.Frontiers in medicine · 2020Article
- Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices.Frontiers in medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur objectives were to explore the changes in the level of interest in risk-sharing agreements (RSAs) in the EU during the last 15 years and the underlying reasons for these changes.
methodsA systematic literature review was conducted using PubMed, Scopus, Web of Science, and Embase. Articles identified were divided into 'quantitative articles' used to establish the level of interest and 'qualitative articles' used to identify the underlying trends in RSAs.
resultsThe literature search retrieved 2144 scientific articles. Data were extracted from 238 articles. Of these, 100 contained quantitative data and 138 contained qualitative data. The pace of articles being published about RSAs grew significantly in 2015, which related to the increase in interest in and knowledge about RSAs. The underlying reasons for the fluctuations were condensed into four overall themes: (1) push for value-based pricing, (2) economic crisis and further push to contain costs, (3) criticism of RSAs in the real world, and (4) diversification of RSAs to fit the purpose.
conclusionThe overall level of interest in RSAs in the EU has been increasing since 2000; therefore, articles reporting the number of RSAs implemented and case studies have been steadily growing as evidence is becoming more readily available. The number of qualitative articles reporting and discussing the underlying reasons for these changes in interest has largely fluctuated over the last 15 years. Despite these fluctuations, interest in RSAs remains high.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.